ProteinQure is a biotech company focused on the design of novel exotic peptides with broad therapeutic applications. Powered by atomic-level simulations and artificial intelligence, we design dynamic peptides that take drugs straight to their target – outperforming other treatment delivery systems. By daring to deliver therapeutics in a novel way we are changing the game for drug development and bringing hope to patients with previously untreatable diseases. At ProteinQure, we pride ourselves on our unique, diverse and cross-disciplinary team that brings together experts from experimental & computational biology, machine learning and software engineering.

We enable the next generation of precision medicine

ProteinQure is a biotech company focused on the design of novel exotic peptides with broad therapeutic applications.

To achieve this goal, we enable the most important new therapeutic classes by allowing therapies to be delivered in a tissue-and cell-specific manner. We use the most advanced computational tools to create novel non-viral delivery methods for the most challenging diseases.

Leveraging the unparalleled computational and predictive power of ProteinStudio™ and a deep understanding of protein structures, the company is focused on creating highly targeted, effective treatments with the potential to transform patient care and outcomes.

We have developed ProteinStudio™ an integrated platform of proprietary technologies to solve complex drug design challenges involving peptides and proteins. Platform validation has been proven both in vitro and in vivo through external Tier 1 pharma partnerships and the development of an internal pipeline of maturing assets for tissue-specific delivery.

ProteinStudio™ harnesses molecular simulations and custom AI models on petascale supercomputers, enabling the creation of unique molecular scaffolds. Our platform seamlessly incorporates thousands of non-natural amino acids and combined with high-quality assays performed in our in-house lab, we can now design unprecedented drug-like peptides with small amounts of data.

Our proprietary peptides can be used to deliver a variety of therapeutic payloads intracellularly via receptor mediated endocytosis.

By precisely targeting specific tissues, our computationally designed peptides optimize therapeutic efficacy and minimize side effects, setting new standards in precision medicine and transforming treatment approaches.

Using ProteinStudio™, our proprietary technology for computational peptide design, we developed high-affinity SORT1-targeting peptides.

We are developing this system to carry and release various therapeutic payloads, including cytotoxic agents, radioisotopes, and oligonucleotides.